Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

AZ And J&J’s Problems Fuel Demand For Pfizer and Moderna COVID-19 Vaccines

Pfizer/BioNTech is emerging as the EU’s partner of choice for COVID-19 vaccines, but others could also benefit.

Commercial Companies

Pivotal Year Ahead For Spain's PharmaMar

The Madrid-based group's Aplidin is set to go back yet again to European regulators but the sea squirt-derived drug seems to be showing more potential in COVID-19 than in multiple myeloma.

Strategy Cancer

Worldwide Novel Drug Launches Soared Amid Pandemic

The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.

Companies Commercial

CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach

Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.

BioPharmaceutical Commercial

Twitchy Times At GSK As Activist Investor Takes Big Stake

GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.   

Strategy Leadership

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Clinical Trials Coronavirus COVID-19

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

BioPharmaceutical Companies

Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform

Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.

Pricing Debate Pricing Strategies

Moderna COVID-19 Boosters Show Preclinical Efficacy Versus South African Variant

While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.

Coronavirus COVID-19 Business Strategies
See All
UsernamePublicRestriction

Register